Details of the Drug

General Information of Drug (ID: DM9BPLW)

Drug Name

Grazoprevir

Synonyms

Grazoprevir; Grazoprevir [INN]; Grazoprevir anhydrous; MK 5172; MK-5172; MK5172; OBMNJSNZOWALQB-NCQNOWPTSA-N; SCHEMBL2175313; (1aR,5S,8S,10R,22aR)-5-tert-butyl-N-{(1R,2S)-1-[(cyclopropanesulfonyl)carbamoyl]-2-ethenylcyclopropyl}-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide; 1350514-68-9; 8YE81R1X1J; CHEBI:132975; CHEMBL2063090; DTXSID50159234; EX-A2253; UNII-8YE81R1X1J

Indication

Disease Entry	ICD 11	Status	REF
Hepatitis C	1E51	Approved	[1]
------------------------------------------------------------------------------------

Affected Organisms

Hepatitis C Virus

ATC Code

J05AP11: Grazoprevir

J05AP: Antivirals for treatment of HCV infections

J05A: DIRECT ACTING ANTIVIRALS

J05: ANTIVIRALS FOR SYSTEMIC USE

J: ANTIINFECTIVES FOR SYSTEMIC USE

Structure

3D MOL is unavailable

2D MOL

#Ro5 Violations (Lipinski): 2

Molecular Weight (mw)

766.9

Logarithm of the Partition Coefficient (xlogp)

4.7

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 0.25-4.0 h [2]
Bioavailability: The bioavailability of drug is 0.93 [2]
Elimination: Grazoprevir is mainly eliminated in the feces (90%) with very little eliminated in the urine (<1%) []
Half-life: The concentration or amount of drug in body reduced by one-half in 31 hours []
Metabolism: The drug is metabolized via oxidative metabolism meditated by CYP3A []
Vd: The volume of distribution (Vd) of drug is 1250 L []

Chemical Identifiers

Formula: C38H50N6O9S
IUPAC Name: (1R,18R,20R,24S,27S)-24-tert-butyl-N-[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetrazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3,5(10),6,8,11-pentaene-27-carboxamide
Canonical SMILES: CC(C)(C)C1C(=O)N2CC(CC2C(=O)NC3(CC3C=C)C(=O)NS(=O)(=O)C4CC4)OC5=NC6=C(C=CC(=C6)OC)N=C5CCCCCC7CC7OC(=O)N1
InChI: OBMNJSNZOWALQB-NCQNOWPTSA-N
InChIKey: 1S/C38H50N6O9S/c1-6-22-19-38(22,35(47)43-54(49,50)25-13-14-25)42-32(45)29-18-24-20-44(29)34(46)31(37(2,3)4)41-36(48)53-30-16-21(30)10-8-7-9-11-27-33(52-24)40-28-17-23(51-5)12-15-26(28)39-27/h6,12,15,17,21-22,24-25,29-31H,1,7-11,13-14,16,18-20H2,2-5H3,(H,41,48)(H,42,45)(H,43,47)/t21-,22-,24-,29+,30-,31-,38-/m1/s1

Cross-matching ID

PubChem CID: 44603531
ChEBI ID: CHEBI:132975
CAS Number: 1350514-68-9
UNII: 8YE81R1X1J
DrugBank ID: DB11575
INTEDE ID: DR0789

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	Pharmacokinetic properties and bioavailability of methimazole. Clin Pharmacokinet. 1985 Sep-Oct;10(5):443-50. doi: 10.2165/00003088-198510050-00006.
3	FDA label of Elbasvir and grazoprevir. The 2020 official website of the U.S. Food and Drug Administration.